Immunomedics is stopping a Phase 3 clinical trial due to “compelling evidence of efficacy” demonstrated in patients with advanced, triple-negative breast cancer, the biotech said Monday.
The decision to halt the study involving the Immunomedics drug called sacituzumab govitecan comes months before final results were expected and was based on a unanimous recommendation of independent study monitors following a review of the data. The monitors also weighed the possibility that the coronavirus pandemic might interfere with the study.
About the Author Reprints
